Related Experiment Videos
Second-line chemotherapy for relapsed small cell lung cancer
1Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
Japanese Journal of Clinical Oncology
|June 1, 1997
Summary
Second-line chemotherapy can effectively treat relapsed small cell lung cancer, with a 33% response rate. Factors like prior response duration positively impact survival, justifying further clinical trials for this condition.
Area of Science:
- Oncology
- Medical Oncology
- Clinical Research
Background:
- Small cell lung cancer (SCLC) frequently relapses after initial treatment.
- Effective treatment strategies for relapsed SCLC are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of second-line chemotherapy in patients with relapsed small cell lung cancer.
- To identify prognostic factors influencing response rates and survival durations in relapsed SCLC.
Main Methods:
- Retrospective analysis of 159 patients with SCLC receiving first-line chemotherapy.
- Assessment of 88 relapsed patients, with 48 receiving second-line chemotherapy.
- Evaluation of response rates, survival times, and correlation with prior treatment parameters.
Main Results:
- First-line chemotherapy achieved a 77% response rate.
- Second-line chemotherapy in relapsed SCLC yielded a 33% response rate (complete or partial).
- Median survival time post-second-line chemotherapy was 146 days; longer response duration and prior response positively impacted survival (P < 0.01).
Conclusions:
- Relapsed small cell lung cancer can still respond to second-line chemotherapy.
- Factors such as duration of response to first-line therapy and time off chemotherapy are significant predictors of survival.
- Further randomized trials are warranted to establish optimal second-line treatment strategies for relapsed SCLC.